Viking's short interest spiked to 30.8%, the highest since 2020, after Phase 2 obesity trial data showed 12.2% weight loss but 28% discontinuations from side effects. Shares plunged 36% last week, yet analysts defended the drug's potency and flexibility, reiterating 'Buy' ratings with $95-$118 targets. On Stocktwits, retail traders stayed 'extremely bullish' despite heavy short bets.